Treatment of diabetic macular oedema in a type 1 diabetes patient – mistakes in interdisciplinary collaboration

Czech version

Authors: M. Veith
Authors‘ workplace: Oftalmologická klinika 3. lékařské fakulty UK a FN Královské Vinohrady Praha, přednosta prof. MUDr. Pavel Kuchynka, CSc.
Published in: Vnitř Lék 2013; 59(3): 231-233
Category: Case Reports

Overview

Diabetic retinopathy (DR) is a significant microvascular complication of diabetes. High quality interdisciplinary collaboration is an important aspect of a successful DR therapy. A case of a 41-year-old diabetic is presented below, who has been in our care for almost four years. His Diabetes ID card only contains his current glycaemia values. Although the patient had been regularly given a report for his diabetologist with a request for additional information, we have only obtained one value of glycated haemoglobin through the course of the patient‘s dispensarisation. For this reason, and the non-stabilisation of DR, we have recommended that the patient starts to see a different diabetologist.

Key words:
diabetic retinopathy – interdisciplinary collaboration

Sources

1. Arevalo JF, Sanchez JG, Wu L et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 116; 2009: 1488–1497.

2. Arevalo JF, Lasave AF, Wu L et al. Intravitreal Bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema.: Results of the Pan-American Collaborative Retina Study Group at 24 Months. Retina 2013; 33: 403–413.

3. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140: 695–702.

4. Bandello F, Berchicci L, La Spina C et al. Evidence for anti-VEGF treatment of diabetic macular edema. Ophthalmic Res 2012; 48: (Suppl. 1): 16–20.

5. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol 2008; 53: 139–149.

6. Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.

7. Diabetic retinopathy Clinical Research Network. A randomized Trial comparing intravitreal triamcinolone acetionicde and focal/grid photocoagulation for diabetic maculoar edema. Ophthalmology 2008; 115: 1447–1459.

8. Dusová J, Studnička J, Rencová E et al. Triamcinolon v léčbě diabetického makulárního edému – roční výsledky. Čes slov Oftal 2008; 64: 149–152.

9. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report No.1. Arch Ophthalmol 1985; 103: 1796–1806.

10. Fraser-Bell S, Kaines A, Hykin PG. Update on treatments for diabetic macular edema. Curr Opin Ophthalmol 2008; 19: 185–189.

11. Gillies MC, Islam FM, Zhu M et al. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol 2007; 91: 1323–1326.

12. Hauser D, Bukelman A, Pokroy R et al. Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg. Retina 2008; 28: 825–830.

13. Chew E, Klein M, Ferris F et al. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Arch Ophthalmol 1996; 114: 1079–1084.

14. Kalvodová B. Screening diabetické retinopatie v ČR – guideline. Čes slov Oftal 2002; 1: 3–10.

15. Kang SW, Sa HS, Cho HY et al. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006; 124: 653–658.

16. Keech AC, Mitchell P, Summanen P et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007; 370: 1687–1697.

17. Kim JE, Pollack JS, Miller DG et al. Isis Study Group: ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008; 28: 735–740.

18. Klein R, Klein B, Moss S et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Int Med 1989; 149: 2427–2432.

19. Klein R, Klein B, Moss E et al. Glycosilated haemoglobin predicts the incidence and progression diabetic retinopathy. JAMA 1988; 260: 2864–2871.

20. Lam DS, Chan CK, Mohamed S et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007; 91: 199–203.

21. Michaelides M, Kaines A, Hamilton RD et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). Ophthalmology 2010; 117: 1078–1086.

22. Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615–625.

23. Ockrim ZK, Sivaprasad S, Falk S et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol 2008; 92: 795–799.

24. Ozkiris A, Evereklioglu C, Erkiliç K et al. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. Eur J Ophthalmol 2004; 14: 543–549.

25. Roth DB, Realini T, Feuer WJ et al. Short-term complications of intravitreal injection of triamcinolone acetonide. Retina 2008; 28: 66–70.

26. Rusňák Š, Fidranská H, Belfínová Š et al. Resopce diabetického cystoidního makulárního edému po intravitreální aplikaci triamcinolon acetonidu v závislosti na kompenzaci základního onemocnění. Čes slov Oftal 2008; 64: 26–29.

27. Řehák J, Chrapek O, Prachařová Z et al. Naše zkušenosti v léčbě diabetické makulopatie. Čes a slov Oftal 2004; 60: 112–117.

28. Schmid KE, Neumaier-Ammerer B, Stolba U et al. Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c). Graefes Arch Clin Exp Ophthalmol 2006; 244: 1446–1152.

29. Sosna T, Švancarová R, Netuková M. Diabetická retinopatie – rizikové faktory, prevence a terapie. Čes a slov Oftal 2010; 66: 195–203.

30. Sosna T, Švancarová R, Netuková M et al. Současný pohled na diabetický makulární edém. Čes a slov Oftal 2012; 68: 91–97.

31. Stewart MW. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr Diabetes Rev 2012; 8: 237–246.

32. Studnička J. Diabetický makulární edém – nové možnosti léčby. Čes a slov Oftal 2012; 68: 61–63.

33. The ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods. Am J Cardiol 2007; 99: (Suppl.): 21–33.

34. UK Prospective Diabetes Study (UKDPS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKDPS 38. BMJ 1998; 317: 703–713.